Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 607-618

  Buchi, Francesca ^a   Spinelli, Elena ^a   Masala, Erico ^a   Gozzini, Antonella ^a   Sanna, Alessandro ^a   Bosi, Alberto ^a   Ferrari, Germano ^a   Santini, Valeria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

AML; Azacitidine; Decitabine; Proteomics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA ENOLASE; ALPHA TUBULIN; AZACITIDINE; BETA TUBULIN; CALRETICULIN; CATALASE; CHAPERONE; CHAPERONIN CONTAINING TCP1; CYCLINE; CYCLOPHILIN A; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1; NUCLEOPHOSMIN; PROTEIN DISULFIDE ISOMERASE; PROTEIN DISULFIDE ISOMERASE A3; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; GENE SEQUENCE; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; REDOX STRESS; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

AZACITIDINE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; ONCOGENE PROTEINS, FUSION; PROTEOMICS;

EID: 84858750876     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.024     Document Type: Article

References (30)

1. Santini V., Kantarjian H.M., Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001, 134:573-586.
2. Santini V. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev Hematol 2009, 2:121-127.
3. Hollenbach P.W., Nguyen A.N., Brady H., Williams M., Ning Y., Richard N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5:e9001.
4. Li L.H., Olin E.J., Buskirk H.H., Reineke L.M. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970, 30:2760-2769.
5. Qiu X., Hother C., Ralfkiaer U.M., Sogaard A., Lu Q., Workman C.T., et al. Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One 2010, 5:e12994.
6. Flotho C., Claus R., Batz C., Schneider M., Sandrock I., Ihde S., et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009, 23:1019-1028.
7. Gozzini A., Rovida E., Dello Sbarba P., Galimberti S., Santini V. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res 2003, 63:8955-8961.
8. Barbetti V., Gozzini A., Rovida E., Morandi A., Spinelli E., Fossati G., et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008, 27:1767-1778.
9. Santini V. A selective activity of DNMTi decitabine on AML1ETO positive cells?. Leuk Res 2007, 31:741-742.
10. Gozzini A., Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8; 21) acute myeloid leukemia blasts. Ann Hematol 2005, 84(Suppl 1):54-60.
11. Berg T., Guo Y., Abdelkarim M., Fliegauf M., Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leuk Res 2007, 31:497-506.
12. Stresemann C., Brueckner B., Musch T., Stopper H., Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006, 66:2794-2800.
13. Ferrari G., Pastorelli R., Buchi F., Spinelli E., Gozzini A., Bosi A., et al. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. J Proteome Res 2007, 6:367-375.
14. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
15. Wijermans P.W., Ruter B., Baer M.R., Slack J.L., Saba H.I., Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008, 32:587-591.
16. Fandy T.E., Herman J.G., Kerns P., Jiemjit A., Sugar E.A., Choi S.H., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
17. Bianchi L., Bruzzese F., Leone A., Gagliardi A., Puglia M., Di Gennaro F., et al. Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. Proteomics 2011, 11:3725-3742.
18. Buchi F., Pastorelli R., Ferrari G., Spinelli E., Gozzini A., Sassolini F., et al. Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. Leuk Res 2011, 35:921-931.
19. Coghlin C., Carpenter B., Dundas S.R., Lawrie L.C., Telfer C., Murray G.I. Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol 2006, 210:351-357.
20. Gold L.I., Eggleton P., Sweetwyne M.T., Van Duyn L.B., Greives M.R., Naylor S.M., et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010, 24:665-683.
21. Lee H.S., Lee J.H., Hur E.H., Lee M.J., Lee J.H., Kim D.Y., et al. Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. Leuk Res 2009, 33:426-433.
22. Voso M.T., Hohaus S., Guidi F., Fabiani E., D'Alo F., Groner S., et al. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 2008, 22:1685-1691.
23. Chen Z.Y., Cai L., Zhu J., Chen M., Chen J., Li Z.H., et al. Fyn requires HnRNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer. Carcinogenesis 2011, 32:1419-1426.
24. Ohshima K., Karube K., Shimazaki K., Kamma H., Suzumiya J., Hamasaki M., et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 2003, 44:1339-1346.
25. Ma Y.L., Peng J.Y., Zhang P., Huang L., Liu W.J., Shen T.Y., et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res 2009, 8:4525-4535.
26. Shi Y., Frost P.J., Hoang B.Q., Benavides A., Sharma S., Gera J.F., et al. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res 2008, 68:10215-10222.
27. Hachiya M., Akashi M. Catalase regulates cell growth in HL60 human promyelocytic cells: evidence for growth regulation by H(2)O(2). Radiat Res 2005, 163:271-282.
28. Satoh K., Berk B.C., Shimokawa H. Vascular-derived reactive oxygen species for homeostasis and diseases. Nitric Oxide 2011, 25:211-215.
29. Song F., Zhang X., Ren X.B., Zhu P., Xu J., Wang L., et al. Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl cis-trans isomerase activity: direct binding between CyPA and the ectodomain of CD147. J Biol Chem 2011, 286:8197-8203.
30. Sedlackova L., Spacek M., Holler E., Imryskova Z., Hromadnikova I. Heat-shock protein expression in leukemia. Tumour Biol 2011, 32:33-44.